RESULTS	The most common adverse events in both groups were asthenia or fatigue ( 270 [ 54 % ] of 503 patients on eribulin and 98 [ 40 % ] of 247 patients on TPC at all grades ) and neutropenia ( 260 [ 52 % ] patients receiving eribulin and 73 [ 30 % ] of those on TPC at all grades ) .\